E. Meijer

发表

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Eiji Higashihara, K. Bae, R. Gansevoort, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.

R. Gansevoort, D. Peters, W. Leonhard, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

J. Li, R. Gansevoort, V. Torres, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study

R. D. de Boer, R. Gansevoort, E. Meijer, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease

R. Gansevoort, D. Peters, Emile de Heer, 2016, American Journal of Nephrology.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

E. J. van der Jagt, R. Gansevoort, R. Renken, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Riding the waves: evidence for a beneficial effect of increased water intake in autosomal dominant polycystic kidney disease patients?

E. Meijer, N. Casteleijn, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.

R. Gansevoort, E. Meijer, P. D. de Jong, 2012, Clinical journal of the American Society of Nephrology : CJASN.

Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease

R. Zietse, R. Gansevoort, E. Meijer, 2011, Kidney and Blood Pressure Research.

Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.

C. Wanner, R. Gansevoort, P. Ravani, 2014, Kidney international.

Sex differences in the association between plasma copeptin and incident type 2 diabetes

R. Gans, H. Hillege, S. Bakker, 2012 .

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

R. Gans, H. Hillege, S. Bakker, 2012, Diabetologia.

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

J. D. de Fijter, J. Wetzels, R. Zietse, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

G. Navis, S. Bakker, R. Gansevoort, 2014, American Society of Nephrology. Clinical Journal.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial

J. D. de Fijter, J. Wetzels, R. Zietse, 2018, JAMA.

Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease

J. D. de Fijter, R. Zietse, R. Gansevoort, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

R. Gansevoort, A. Chapman, V. Torres, 2016, Nephrology, Dialysis and Transplantation.

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

C. Wanner, R. Gansevoort, P. Ravani, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

University of Groningen Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease Spithoven,

M. Greuter, R. Gansevoort, P. Jong, 2016 .

Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease

E. J. van der Jagt, M. Greuter, R. Gansevoort, 2015, European Radiology.

Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for clinical practice

R. Gansevoort, E. Meijer, 2021, Current opinion in nephrology and hypertension.

Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors

R. Gansevoort, M. Losekoot, D. Peters, 2019, American Journal of Nephrology.

Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease

J. D. de Fijter, J. Wetzels, R. Zietse, 2018, BMC Nephrology.

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.

E. J. van der Jagt, G. Navis, S. Bakker, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients

J. D. de Fijter, J. Wetzels, R. Zietse, 2019, Kidney international reports.

Glomerular and tubular damage markers in individuals with progressive albuminuria.

S. Bakker, R. Gansevoort, E. Meijer, 2013, Clinical journal of the American Society of Nephrology : CJASN.

Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations

R. Gansevoort, M. Losekoot, D. Peters, 2020, Kidney international reports.

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.

R. Gansevoort, E. Meijer, B. Kramers, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan

R. Gansevoort, E. Meijer, B. Kramers, 2018, BMC Nephrology.

Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients

V. Torres, E. Meijer, E. Higashihara, 2017, Clinical and Experimental Nephrology.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

J. D. de Fijter, J. Wetzels, R. Zietse, 2019, Gastroenterology.

Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.

R. Gansevoort, E. Meijer, Debbie Zittema, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.

Lyanne M. Kieneker, O. Melander, B. Balkau, 2018, JCI insight.

Renal disease progression in autosomal dominant polycystic kidney disease

E. Meijer, 2010 .

Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability.

R. Gansevoort, E. Meijer, 2020, Kidney international.

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD

J. D. de Fijter, J. Wetzels, R. Zietse, 2019, Kidney international reports.

Vivo Endothelial Growth Factor In Vitro and In Akt-Dependent Expression of Vascular Endothelial Cells Results in mTORC 2-and CD 40-Induced Signaling in Human

E. Meijer, O. Dormond, D. Briscoe, 2008 .

CD40-Induced Signaling in Human Endothelial Cells Results in mTORC2- and Akt-Dependent Expression of Vascular Endothelial Growth Factor In Vitro and In Vivo1

E. Meijer, O. Dormond, D. Briscoe, 2008, The Journal of Immunology.

Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease

R. Gansevoort, E. Meijer, T. Bais, 2022, Drugs.

Prophylaxis with low‐dose low‐molecular‐weight heparin during pregnancy and postpartum: is it effective?

J. Middeldorp, F. Klumper, E. Meijer, 2011, Journal of thrombosis and haemostasis : JTH.

Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.

R. Gansevoort, E. Meijer, H. van Goor, 2015, Clinical journal of the American Society of Nephrology : CJASN.

Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19

A. M. Ramos, L. Rimsevicius, Dan Constantin Radulescu, 2022, Transplantation.

Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy

J. Wetzels, E. Meijer, H. P. Peters, 2016, Annals of clinical biochemistry.

Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

E. J. van der Jagt, G. Navis, S. Bakker, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.

Adriana V Gregory, Adriana V. Gregory, T. Kline, 2021, American journal of human genetics.

Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD

H. Heerspink, R. Gansevoort, Hui Li, 2022, Clinical journal of the American Society of Nephrology : CJASN.

Estimation of total kidney volume in autosomal dominant polycystic kidney disease.

J. D. de Fijter, J. Wetzels, R. Zietse, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

G. Navis, R. Gansevoort, E. Meijer, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.

T. Rabelink, S. Bakker, R. Gansevoort, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Modifiable factors associated with copeptin concentration: a general population cohort.

S. Bakker, R. Gansevoort, E. Meijer, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Lyanne M. Kieneker, L. Rimsevicius, U. Maggiore, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

J. D. de Fijter, J. Wetzels, R. Gansevoort, 2016, Drug Safety.

The Need for Routine Native Nephrectomy in the Workup for Kidney Transplantation in Autosomal Dominant Polycystic Kidney Disease Patients

R. Gansevoort, E. Meijer, Iris W. Koorevaar, 2022, Urologia Internationalis.

Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease.

W. Oyen, J. D. de Fijter, R. Zietse, 2018, The Netherlands journal of medicine.

[Autosomal dominant polycystic kidney disease: new insights and possible drugs].

E. J. van der Jagt, R. Gansevoort, M. Breuning, 2009, Nederlands tijdschrift voor geneeskunde.

Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease

R. Gansevoort, E. Meijer, N. Casteleijn, 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The impact of pre-transplantation nephrectomy on quality of life in patients with autosomal dominant polycystic kidney disease

J. D. de Fijter, R. Gansevoort, E. Meijer, 2023, World Journal of Urology.

Copeptin, a Surrogate Marker of Vasopressin, Is Associated With Accelerated Renal Function Decline in Renal Transplant Recipients

J. J. Homan van der Heide, S. Bakker, R. Gansevoort, 2009, Transplantation.

Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?

S. Bakker, R. Gansevoort, E. Meijer, 2015, American Journal of Nephrology.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

S. Bakker, R. Gansevoort, E. Meijer, 2013, Kidney international.

Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.

S. Bakker, R. Gansevoort, E. Meijer, 2010, Kidney international.

The epidermal growth factor receptor pathway in chronic kidney diseases

R. Gansevoort, E. Meijer, H. Goor, 2016, Nature Reviews Nephrology.

Somatostatin in renal physiology and autosomal dominant polycystic kidney disease

R. Gansevoort, E. Meijer, N. Casteleijn, 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Early renal abnormalities in autosomal dominant polycystic kidney disease.

E. J. van der Jagt, G. Navis, R. Gansevoort, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.

J. D. de Fijter, J. Wetzels, R. Zietse, 2020, Kidney international.

Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study

N. Perico, R. Gansevoort, A. Caroli, 2022, Clinical kidney journal.

High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.

J. Wetzels, E. Meijer, H. van Goor, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Stability of tubular damage markers epidermal growth factor and heparin-binding EGF-like growth factor in urine

R. Gansevoort, E. Meijer, H. van Goor, 2019, Clinical chemistry and laboratory medicine.

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression

J. Burgerhof, R. Gansevoort, M. Losekoot, 2017, Kidney international reports.

Better understanding of ADPKD results in potential new treatment options: ready for the cure?

R. Gansevoort, D. Peters, E. Meijer, 2008, JN. Journal of Nephrology (Milano. 1992).

Urinary biomarkers in autosomal dominant polycystic kidney disease: is there no prognostic value?

R. Gansevoort, E. Meijer, W. Boertien, 2012, Kidney international.

International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection

W. Oyen, F. Nevens, G. Rangan, 2016, Nephron.

U. Maggiore, D. Abramowicz, M. Christiaans, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection.